{"created":"2021-03-01T06:10:09.565292+00:00","id":6262,"links":{},"metadata":{"_buckets":{"deposit":"a2b64a42-d53e-41a4-af25-5409e06500a6"},"_deposit":{"id":"6262","owners":[],"pid":{"revision_id":0,"type":"depid","value":"6262"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00006262","sets":["453:456","471:537:568:591"]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2003-09","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"85","bibliographicPageStart":"79","bibliographicVolumeNumber":"51","bibliographic_titles":[{"bibliographic_title":"Acta medica et biologica"},{"bibliographic_title":"Acta medica et biologica","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: The aim of the present study was to examine the effects of an angiotensin-II-receptor antagonist, valsartan, on echocardiographically proven left ventricular hypertrophy in patients with Type 2 diabetes. Methods: Patients received a low dose of valsartan for 6 months. This low dose has no clinical effect on blood pressure. Echocardiographic data of 37 patients were analyzed. Results: After 6 months of valsartan therapy, the overall mean left ventricular mass index decreased slightly, from 109.0±26.1 to 108.1±22.0 g/m^2 (n=37). However a significant decrease was observed in the subgroup of patients with LVH (n=16), from 128.3±22.9 to 121.9±23.3 g/m^2 (P<0.05). There were no significant differences before and after treatment in body mass index, HbA_<1c>, or systolic or diastolic blood pressure. Conclusion: In Type 2 diabetic patients with left ventricular hypertrophy, treatment with valsartan for 6 months reduced the left ventricular mass index with no fall in systemic blood pressure.","subitem_description_type":"Abstract"}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Niigata University School of Medicine"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA00508361","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"05677734","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"SUZUKI, Katsunori"}],"nameIdentifiers":[{"nameIdentifier":"51998","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"KATO, Kiminori"}],"nameIdentifiers":[{"nameIdentifier":"51999","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"SOUDA, Satoshi"}],"nameIdentifiers":[{"nameIdentifier":"52000","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"AIZAWA, Yoshifusa"}],"nameIdentifiers":[{"nameIdentifier":"52001","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-06"}],"displaytype":"detail","filename":"KJ00000007374.pdf","filesize":[{"value":"7.4 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"KJ00000007374.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/6262/files/KJ00000007374.pdf"},"version_id":"899a7342-5966-4a31-b1bc-6231615bb12e"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"left ventricular hypertrophy","subitem_subject_scheme":"Other"},{"subitem_subject":"valsartan","subitem_subject_scheme":"Other"},{"subitem_subject":"Type 2 diabetes mellitus","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Effect of Valsartan, an Angiotensin-II-Receptor Antagonist, on Left Ventricular Hypertrophy in Type 2 Diabetic Patients","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Effect of Valsartan, an Angiotensin-II-Receptor Antagonist, on Left Ventricular Hypertrophy in Type 2 Diabetic Patients"},{"subitem_title":"Effect of Valsartan, an Angiotensin-II-Receptor Antagonist, on Left Ventricular Hypertrophy in Type 2 Diabetic Patients","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","591"],"pubdate":{"attribute_name":"公開日","attribute_value":"2007-05-10"},"publish_date":"2007-05-10","publish_status":"0","recid":"6262","relation_version_is_last":true,"title":["Effect of Valsartan, an Angiotensin-II-Receptor Antagonist, on Left Ventricular Hypertrophy in Type 2 Diabetic Patients"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:39:37.022720+00:00"}